DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Abrocitinib 200 MG Oral Tablet
Drug: Ritlecitinib
Drug: Placebo

First Posted Date: 2023-02-24

Last Posted Date: 2024-10-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 78

Registration Number: NCT05743244

Locations: 🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
University of California- San Francisco, San Francisco, California, United States

and more 17 locations

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2

Recruiting

Conditions: Metastatic Neuroendocrine Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lutetium Lu 177 Dotatate
Procedure: Magnetic Resonance Imaging
Drug: Triapine

First Posted Date: 2023-02-13

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT05724108

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 23 locations

Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant

Not yet recruiting

Conditions: Hematopoietic Stem Cell Transplant

First Posted Date: 2023-02-10

Last Posted Date: 2025-05-23

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 500

Registration Number: NCT05722210

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Phase 2

Recruiting

Conditions: Advanced Rare Malignant Solid Neoplasm
Rare Malignant Solid Neoplasm
Refractory Rare Malignant Solid Neoplasm

Interventions: Biological: Atezolizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Drug: Tiragolumab

First Posted Date: 2023-02-08

Last Posted Date: 2025-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT05715281

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Phase 2

Not yet recruiting

Conditions: Insulin Resistance
Obesity

Interventions: Drug: Mirabegron
Drug: Placebo
Drug: Alpha-lipoic acid

First Posted Date: 2023-02-06

Last Posted Date: 2025-05-23

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 60

Registration Number: NCT05713799

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 3

Withdrawn

Conditions: Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bendamustine
Drug: Brentuximab Vedotin
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Etoposide
Drug: Gemcitabine
Drug: Ifosfamide
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Procedure: Positron Emission Tomography
Biological: Pembrolizumab
Radiation: Radiation Therapy
Other: Transplant Conditioning
Drug: Vinorelbine

First Posted Date: 2023-02-03

Last Posted Date: 2024-03-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05711628

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Phase 1

Recruiting

Conditions: Metastatic Dedifferentiated Liposarcoma
Metastatic Leiomyosarcoma
Metastatic Myxofibrosarcoma
Metastatic Sarcoma
Metastatic Synovial Sarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma
Unresectable Dedifferentiated Liposarcoma
Unresectable Leiomyosarcoma
Unresectable Myxofibrosarcoma
Unresectable Sarcoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Peposertib

First Posted Date: 2023-02-03

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05711615

Locations: 🇺🇸
UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
🇺🇸
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 11 locations

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Phase 2

Recruiting

Conditions: Actinic Keratosis

Interventions: Procedure: Biopsy
Drug: Calcipotriene
Drug: Fluorouracil

First Posted Date: 2023-01-26

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT05699603

Locations: 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 1 locations

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: pH Low Insertion Peptide-exatecan Conjugate CBX-12

First Posted Date: 2023-01-20

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT05691517

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Phase 2

Suspended

Conditions: Localized Osteosarcoma
Metastatic Osteosarcoma
Secondary Osteosarcoma
High Grade Osteosarcoma

Interventions: Procedure: Bone Scan
Drug: Cabozantinib S-malate
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Doxorubicin Hydrochloride
Procedure: Magnetic Resonance Imaging
Drug: Methotrexate
Procedure: Surgical Procedure
Procedure: X-Ray Imaging

First Posted Date: 2023-01-20

Last Posted Date: 2025-05-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1122

Registration Number: NCT05691478

Locations: 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸
State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸
Alfred I duPont Hospital for Children, Wilmington, Delaware, United States

and more 89 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy